Feasibility of using machine learning on insurance claims to identify correlates of lower extremity amputation in insured adults with type 2 diabetes who initiate treatment with sodium-glucose co-transporter 2 (SGLT-2) inhibitors
You must log in to view this content. All contents are accessible to AMIA members and meeting attendees. If you are interested in purchasing proceedings, please contact us at mail@amia.org